SCHEMBL4038409

SCHEMBL4038409

O=C(NC1CCCCC1)C(C1CCCCC1)C1(c2sccc2Cl)Nc2cc(F)c(Cl)cc2N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.41
NPC1 O15118 6/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP3A4 P08684 4/20 0.40
KCNH2 Q12809 3/20 0.40
NR1H4 Q96RI1 3/20 0.40
LMNA P02545 1/20 0.37
CYP2C9 P11712 3/20 0.35
CYP2D6 P10635 2/20 0.35
POLB P06746 2/20 0.35
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
EPHX2 P34913 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
GAA P10253 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037758 0.83 CYP3A4 (0.41) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4036578 0.83 KCNH2 (0.48) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4038655 0.83 KCNH2 (0.48) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4034374 0.83 KCNH2 (0.48) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4038777 0.83 CYP3A4 (0.42) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4039537 0.83 KCNH2 (0.48) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4042942 0.83 CYP3A4 (0.42) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4036376 0.83 KCNH2 (0.48) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4036896 0.81 NR1H4 (0.42) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2
SCHEMBL4038118 0.80 NR1H4 (0.44) RAB9ANPC1SMN1; SMN2CYP3A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed